HMOX1 and breast cancer: A 42-day FMD in combination with chemotherapy in a mice model showed that FMD delayed the progression of breast cancer and melanoma by increasing the number of common lymphoid progenitor cells and cytotoxic CD8+ tumor-infiltrating lymphocytes in the bone marrow, alongside down-regulating the expression level of the stress response enzyme heme oxygenase-1 [60].